ArticleThe Journal of experimental medicine2018
Zebrafish blastomere screen identifies retinoic acid suppression of
Open access · hybridAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 73 citations in OpenAlex.
- A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).Cancer · 2024Trial
- Combined all-trans retinoic acid with low-dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single-center, secondary analysis of a phase II study.Cancer medicine · 2023Trial
- Characteristics of fusion genes in breast cancer.Cancer cell international · 2026Review
- Analysis of metabolic characteristics of epristeride in zebrafish based on LC-Q-TOF MS and its potential applications in doping control.RSC advances · 2026Article
- Clinical Characteristics, Treatment and Prognosis of Primary Tracheal Adenoid Cystic Carcinoma: A Multicenter Retrospective Study.Cancer medicine · 2025Article
- Oxidative phosphorylation is a key feature of neonatal monocyte immunometabolism promoting myeloid differentiation after birth.Nature communications · 2025Article
- Salivary Gland Cancers in the Era of Molecular Analysis: The Role of Tissue and Liquid Biomarkers.Cancers · 2025Review
- BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia.JCI insight · 2024Article
- A conserved transcription factor regulatory program promotes tendon fate.Developmental cell · 2024Article
- What value do zebrafish have to anticancer drug discovery?Expert opinion on drug discovery · 2024Article
- Zebrafish-A Suitable Model for Rapid Translation of Effective Therapies for Pediatric Cancers.Cancers · 2024Review
- Transcription Factor MYB as Therapeutic Target: Current Developments.International journal of molecular sciences · 2024Review
- Emerging role of MYB transcription factors in cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Heterogeneous immune landscapes and macrophage dynamics in primary and lung metastatic adenoid cystic carcinoma of the head and neck.Frontiers in immunology · 2024Article
- Identification of side effects of COVID-19 drug candidates on embryogenesis using an integrated zebrafish screening platform.Scientific reports · 2023Article
- Flight for fish in drug discovery: a review of zebrafish-based screening of molecules.Biology letters · 2023Review
- Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma.Journal of the National Cancer Institute · 2023Article
- Zebrafish as a Model to Study Retinoic Acid Signaling in Development and Disease.Biomedicines · 2023Review
- Article
- Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments.Current treatment options in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Joseph MandelbaumStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA.
Ilya A ShestopalovStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA.
Rachel E HendersonStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA.
Nicole G ChauDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Birgit KnoechelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Michael J WickSouth Texas Accelerated Research Therapeutics, San Antonio, TX.
Leonard I ZonStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA zon@enders.tch.harvard.edu.ORCID 0000-0003-0860-926X
Boston Children's Hospital · USBroad Institute · USDana-Farber Cancer Institute · USSouth Texas Accelerated Research Therapeutics · US
Funding
TRANSCRIPTION FACTOR GATA-1 IN TERMINAL ERYTHROID DEVELOPMENTP01HL032262 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ORKIN, STUART H · 1985 to 2021
$38.9MTranscriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DAVID E FISHER · 2013 to 2026
$25.3MCORE--ZEBRAFISHP30DK049216 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI ZHOU, YI · 1999 to 2015
$14.3MCustomized stem cells for clinical application in blood disordersR24DK092760 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI COLLINS, JAMES J, DALEY, GEORGE Q · 2011 to 2018
$10.7MHuman Pluripotent Stem Cell and Progenitor Models of Cardiac and Blood DiseasesU01HL100001 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI DALEY, GEORGE Q, ORKIN, STUART H · 2009 to 2015
$8.9MStem cells for therapeutics discovery in genetic blood disordersU01HL134812 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI DALEY, GEORGE Q, LIPTON, JEFFREY M · 2016 to 2022
$8.3MCancer Biology in the ZebrafishR01CA103846 · NCI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 2003 to 2022
$7.5MProject-002U54DK110805 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI ORKIN, STUART H, ZON, LEONARD IRA · 2016 to 2020
$5.9MEMBRYONIC HEMATOPOIESISR01HL048801 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 1992 to 2016
$5.7MCOMPARATIVE APPROACH TO GLOBIN REGULATION/THALASSEMIAR01DK053298 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 1998 to 2012
$3.9MEpigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemiaK08CA191091 · NCI · DANA-FARBER CANCER INST · PI KNOECHEL, BIRGIT · 2015 to 2019
$886kHoward Hughes Medical InstituteNCI NIH HHS K08 CA191091NCI NIH HHS P01 CA163222NCI NIH HHS R01 CA103846NHLBI NIH HHS P01 HL032262NHLBI NIH HHS R01 HL048801NHLBI NIH HHS U01 HL100001NHLBI NIH HHS U01 HL134812NIDDK NIH HHS P30 DK049216NIDDK NIH HHS R01 DK053298NIDDK NIH HHS R24 DK092760NIDDK NIH HHS U54 DK110805
Abstract
Pluripotent cells have been used to probe developmental pathways that are involved in genetic diseases and oncogenic events. To find new therapies that would target
Indexed as
AnimalsBlastomeresCarcinoma, Adenoid CysticHumansMiceMice, NudeProto-Oncogene Proteins c-mybSalivary Gland NeoplasmsTretinoinU937 CellsXenograft Model Antitumor AssaysZebrafishZebrafish ProteinsProto-Oncogene Proteins c-mybTretinoinZebrafish Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.